1-Hydroxymethyl-4-methyl-bicyclo<2.1.1>hexan | 4840-02-2

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1-Hydroxymethyl-4-methyl-bicyclo<2.1.1>hexan
• 英文别名: (4-Methyl-1-bicyclo[2.1.1]hexanyl)methanol
• CAS: 4840-02-2
• 化学式: C₈H₁₄O
• 分子量: 126.199
• InChiKey: GSFVBKLZOPHTBW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  4-Methyl-bicyclo<2.1.1>hexan-carbonitril 在 lithium aluminium tetrahydride 作用下， 以 乙醚 为溶剂， 生成 1-Hydroxymethyl-4-methyl-bicyclo<2.1.1>hexan
  参考文献：
  名称：

  Bicyclo[1.1.0]butane Chemistry. II. Cycloaddition Reactions of 3-Methylbicyclo[1.1.0]butanecarbonitriles. The Formation of Bicyclo[2.1.1]hexanes

  摘要：

  DOI：

  10.1021/ja00955a021

文献信息

• [EN] CHEMICAL COMPOUNDS<br/>[FR] COMPOSÉS CHIMIQUES
  申请人：GLAXOSMITHKLINE IP DEV LTD

  公开号：WO2020012339A1

  公开（公告）日：2020-01-16

  The invention is directed to substituted carbon-linked bicycloalkane derivatives. Specifically, the invention is directed to compounds according to Formula (X): (X) wherein C', D', L2', L3', R1', R2', R3', R4', R5', R6', R7', R8', z1', z2', z3', z4', z5', z6', X1, and X2 are as defined herein; or a salt thereof including a pharmaceutically acceptable salt thereof. The compounds of the invention are inhibitors of the ATF4 pathway and can be useful in the treatment of cancer, pre-cancerous syndromes and diseases associated with activated unfolded protein response pathways, such as Alzheimer's disease, spinal cord injury, traumatic brain injury, ischemic stroke, stroke, diabetes, Parkinson disease, Huntington's disease, Creutzfeldt-Jakob Disease, and related prion diseases, progressive supranuclear palsy, amyotrophic lateral sclerosis, myocardial infarction, cardiovascular disease, inflammation, fibrosis, chronic and acute diseases of the liver, chronic and acute diseases of the lung, chronic and acute diseases of the kidney, chronic traumatic encephalopathy (CTE), neurodegeneration, dementia, cognitive impairment, atherosclerosis, ocular diseases, neurological disorders, pain, arrhythmias, in organ transplantation and in the transportation of organs for transplantation. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting the ATF4 pathway and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.